Cargando…
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generalizable exposure‐response analysis approach to determi...
Autores principales: | Jones, Aksana K., Salem, Ahmed Hamed, Freise, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430154/ https://www.ncbi.nlm.nih.gov/pubmed/30659774 http://dx.doi.org/10.1002/psp4.12380 |
Ejemplares similares
-
A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses
por: Jonsson, E. Niclas, et al.
Publicado: (2022) -
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
por: Mould, DR, et al.
Publicado: (2015) -
Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development
por: Overgaard, RV, et al.
Publicado: (2015) -
DementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses
por: Lanzi, Alyssa M., et al.
Publicado: (2023) -
Constrained Optimization for Decision Making in Health Care Using Python: A Tutorial
por: Leung, K. H. Benjamin, et al.
Publicado: (2023)